Emergent BioSolutions Inc. announced that it has secured an indefinite-delivery, indefinite-quantity (IDIQ) procurement contract with a maximum value up to $235.8 million to supply BioThrax (Anthrax Vaccine Adsorbed) for use by all branches of the U.S. military as Pre-Exposure Prophylaxis (PrEP) for anthrax disease. The new contract with the U.S. Department of Defense (DoD) and led by the Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense, is comprised of a five-year base agreement ending on September 30, 2028, and an additional five-year option that would extend the contract to September 30, 2033. Under the initial five-year IDIQ contract, there is a guaranteed purchase minimum of $20.1 million, with future orders estimated to be at least $20 million for each following year for a total award value up to $235.8 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
12.11 USD | +7.07% | +38.88% | +404.58% |
09/07 | Emergent Biosolutions, Johnson & Johnson Settle Dispute Over COVID-19 Vaccine Manufacturing | MT |
08/07 | Emergent, J&J settle COVID vaccine supply deal dispute | RE |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+404.58% | 593M | |
+61.53% | 856B | |
+38.95% | 631B | |
-3.66% | 359B | |
+15.06% | 325B | |
+9.18% | 297B | |
+5.89% | 234B | |
+16.53% | 226B | |
+15.67% | 177B | |
+2.47% | 165B |
- Stock Market
- Equities
- EBS Stock
- News Emergent BioSolutions Inc.
- Emergent BioSolutions Receives Procurement Contract to Supply BioThrax (Anthrax Vaccine Adsorbed) to the U.S. Department of Defense